个人中心 - 老虎社区

Cheetah89

IP属地：未知

帖子 · 47帖子 · 47
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- Cheetah89Cheetah89
  ·2021-08-06
  Great
  非常抱歉，此主贴已删除
  1,332 1
  4
  分享
  举报
- Cheetah89Cheetah89
  ·2021-08-04
  Fastastic
  Most of Chinese stocks rally in premarket trading
  (Aug 4) Most of Chinese stocks rally in premarket trading.
  Most of Chinese stocks rally in premarket trading
  2,119 评论
  2
  分享
  举报
- Cheetah89Cheetah89
  ·2021-07-28
  Great
  非常抱歉，此主贴已删除
  1,573 1
  1
  分享
  举报
- Cheetah89Cheetah89
  ·2021-07-17
  Right On
  非常抱歉，此主贴已删除
  2,424 评论
  点赞
  分享
  举报
- Cheetah89Cheetah89
  ·2021-07-12
  Great outcome
  非常抱歉，此主贴已删除
  2,103 1
  3
  分享
  举报
- Cheetah89Cheetah89
  ·2021-07-09
  Drop drop
  U.S. FDA narrows patient group for Biogen's Alzheimer's drug
  July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can u
  U.S. FDA narrows patient group for Biogen's Alzheimer's drug
  1,593 评论
  点赞
  分享
  举报
- Cheetah89Cheetah89
  ·2021-06-29
  Good
  Boeing’s Newest Jet Is Delayed. Other Issues Are More Important.
  The commercial aerospace giant Boeing got a bit of bad news about its latest 777 jet, the 777X. The
  Boeing’s Newest Jet Is Delayed. Other Issues Are More Important.
  1,734 评论
  2
  分享
  举报
- Cheetah89Cheetah89
  ·2021-06-27
  Yes
  非常抱歉，此主贴已删除
  1,369 2
  2
  分享
  举报
- Cheetah89Cheetah89
  ·2021-06-24
  Good
  非常抱歉，此主贴已删除
  1,191 评论
  1
  分享
  举报
- Cheetah89Cheetah89
  ·2021-06-24
  Soon.
  非常抱歉，此主贴已删除
  1,863 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3583233379322937","uuid":"3583233379322937","gmtCreate":1620139355025,"gmtModify":1620612174940,"name":"Cheetah89","pinyin":"cheetah89","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":121,"tweetSize":47,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":893858390,"gmtCreate":1628256743410,"gmtModify":1631889786765,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/893858390","repostId":"1141271021","repostType":4,"isVote":1,"tweetType":1,"viewCount":1332,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890335525,"gmtCreate":1628082648567,"gmtModify":1631889786768,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Fastastic","listText":"Fastastic","text":"Fastastic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/890335525","repostId":"1138278557","repostType":4,"repost":{"id":"1138278557","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628069771,"share":"https://www.laohu8.com/m/news/1138278557?lang=&edition=full","pubTime":"2021-08-04 17:36","market":"us","language":"en","title":"Most of Chinese stocks rally in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1138278557","media":"Tiger Newspress","summary":"(Aug 4) Most of Chinese stocks rally in premarket trading.","content":"<p>(Aug&nbsp;4)&nbsp;Most&nbsp;of&nbsp;Chinese&nbsp;stocks&nbsp;rally&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1e20b3f08685e4cdc45bf7c333cb5e6f\" tg-width=\"373\" tg-height=\"729\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Most of Chinese stocks rally in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMost of Chinese stocks rally in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-04 17:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Aug&nbsp;4)&nbsp;Most&nbsp;of&nbsp;Chinese&nbsp;stocks&nbsp;rally&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1e20b3f08685e4cdc45bf7c333cb5e6f\" tg-width=\"373\" tg-height=\"729\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138278557","content_text":"(Aug 4) Most of Chinese stocks rally in premarket trading.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":2119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801195664,"gmtCreate":1627486274458,"gmtModify":1631889786772,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/801195664","repostId":"1131233069","repostType":4,"isVote":1,"tweetType":1,"viewCount":1573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170778350,"gmtCreate":1626457946470,"gmtModify":1631889786775,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Right On","listText":"Right On","text":"Right On","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170778350","repostId":"1130848269","repostType":4,"isVote":1,"tweetType":1,"viewCount":2424,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142018359,"gmtCreate":1626103495471,"gmtModify":1631889786777,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Great outcome","listText":"Great outcome","text":"Great outcome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/142018359","repostId":"2150539769","repostType":4,"isVote":1,"tweetType":1,"viewCount":2103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143375771,"gmtCreate":1625768448093,"gmtModify":1631889786780,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Drop drop&nbsp;","listText":"Drop drop&nbsp;","text":"Drop drop","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143375771","repostId":"1184325113","repostType":4,"repost":{"id":"1184325113","kind":"news","pubTimestamp":1625750497,"share":"https://www.laohu8.com/m/news/1184325113?lang=&edition=full","pubTime":"2021-07-08 21:21","market":"us","language":"en","title":"U.S. FDA narrows patient group for Biogen's Alzheimer's drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1184325113","media":"Reuters","summary":"July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can u","content":"<p>July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can use its Alzheimer’s disease drug, after the agency drew sharp criticism for approving the drug last month without proof of clear benefit against the disease.</p>\n<p>Shares of the company fell nearly 3% before the bell on Thursday.</p>\n<p>The U.S. Food and Drug Administration has been criticized for its decision to allow wide use of Biogen’s Aduhelm among patients even though the company had tested the drug only in patients with early disease who tested positive for a component of amyloid brain plaques.</p>\n<p>Aduhelm, also known as aducanumab, was approved despite a lack of clear evidence showing the drug worked and against the advice of an outside group of advisers.</p>\n<p>Several members of the FDA’s advisory panel have resigned in protest over the approval.</p>\n<p>Biogen said it had asked for an update to the label, a written information that accompanies a drug, after “dialogue with FDA, physicians and patient advocates.” “The intent is to help prescribing physicians to engage with patients,” Biogen said in a statement.</p>\n<p>The new label says that treatment with the drug should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.</p>\n<p>It also says there is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.</p>\n<p>The new patient population is largely in-line with how the drug was expected to be used, Truist Securities analyst Robyn Karnauskas said in a note. She expects roughly $12 billion in peak sales by 2031.</p>\n<p>Biogen’s drug has been hailed by patient advocates and some neurologists eager for a treatment for the memory-robbing disease. Other doctors said clinical trial results were inconsistent and more proof was needed.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. FDA narrows patient group for Biogen's Alzheimer's drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. FDA narrows patient group for Biogen's Alzheimer's drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 21:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/biogen-alzheimers-fda/update-2-u-s-fda-narrows-patient-group-for-biogens-alzheimers-drug-idUSL3N2OK2XT><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can use its Alzheimer’s disease drug, after the agency drew sharp criticism for approving the drug last ...</p>\n\n<a href=\"https://www.reuters.com/article/biogen-alzheimers-fda/update-2-u-s-fda-narrows-patient-group-for-biogens-alzheimers-drug-idUSL3N2OK2XT\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.reuters.com/article/biogen-alzheimers-fda/update-2-u-s-fda-narrows-patient-group-for-biogens-alzheimers-drug-idUSL3N2OK2XT","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184325113","content_text":"July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can use its Alzheimer’s disease drug, after the agency drew sharp criticism for approving the drug last month without proof of clear benefit against the disease.\nShares of the company fell nearly 3% before the bell on Thursday.\nThe U.S. Food and Drug Administration has been criticized for its decision to allow wide use of Biogen’s Aduhelm among patients even though the company had tested the drug only in patients with early disease who tested positive for a component of amyloid brain plaques.\nAduhelm, also known as aducanumab, was approved despite a lack of clear evidence showing the drug worked and against the advice of an outside group of advisers.\nSeveral members of the FDA’s advisory panel have resigned in protest over the approval.\nBiogen said it had asked for an update to the label, a written information that accompanies a drug, after “dialogue with FDA, physicians and patient advocates.” “The intent is to help prescribing physicians to engage with patients,” Biogen said in a statement.\nThe new label says that treatment with the drug should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.\nIt also says there is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.\nThe new patient population is largely in-line with how the drug was expected to be used, Truist Securities analyst Robyn Karnauskas said in a note. She expects roughly $12 billion in peak sales by 2031.\nBiogen’s drug has been hailed by patient advocates and some neurologists eager for a treatment for the memory-robbing disease. Other doctors said clinical trial results were inconsistent and more proof was needed.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":1593,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150669022,"gmtCreate":1624896535366,"gmtModify":1631889786785,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150669022","repostId":"1184667820","repostType":4,"repost":{"id":"1184667820","kind":"news","pubTimestamp":1624890163,"share":"https://www.laohu8.com/m/news/1184667820?lang=&edition=full","pubTime":"2021-06-28 22:22","market":"us","language":"en","title":"Boeing’s Newest Jet Is Delayed. Other Issues Are More Important.","url":"https://stock-news.laohu8.com/highlight/detail?id=1184667820","media":"Barrons","summary":"The commercial aerospace giant Boeing got a bit of bad news about its latest 777 jet, the 777X. The ","content":"<p>The commercial aerospace giant Boeing got a bit of bad news about its latest 777 jet, the 777X. The Federal Aviation Administration told the company recently the jet likely won’t be approved for commercial service until mid-2023.</p>\n<p>That timeline, contained in a May letter from the regulator to the company, is longer than investors might have expected, but it isn’t actually all that bad for the stock. Boeing didn’t immediately reply to a request for comment.</p>\n<p>The 777X took its maiden test flight back in&nbsp;January 2020. That might have put it on track to be approved by mid-2021, based on the way the industry worked a few years ago. Consider that the&nbsp;737 MAX&nbsp;jet took its initial flight in early 2016 and was approved for service about 14 months later. Deliveries began around mid-2017.</p>\n<p>But the MAX, of course, was grounded in March 2019 following two deadly crashes within five months. It took&nbsp;20-plus months&nbsp;of design modifications, additional testing, and regulatory oversight, for Boeing to win permission for the jet to carry passengers again.</p>\n<p>The MAX situation caused changes at Boeing, including new&nbsp;safety committees, as well as alterations to the FAA’s&nbsp;oversight process. Those shifts could be stretching out the approval process for new planes. The pandemic probably didn’t help the 777x approval timeline either.</p>\n<p>Regardless of the reasons, the approval process has been slow. Boeing investors aren’t thrilled with news of the delay, although deliveries of MAX jets and the recovery of the commercial aerospace business are bigger concerns. Shares were down about 2.8% at $241.56 in early trading, while the&nbsp;S&amp;P 500&nbsp;and&nbsp;Dow Jones Industrial Average&nbsp;were nearly flat.</p>\n<p>Vertical Research Partners analyst&nbsp;Rob Stallard&nbsp;summed up all of the positives and negatives for Boeing in a Monday report. The 777X delay is a regulatory problem, but it is only one of three he mentioned. China, for instance, hasn’t reapproved the 737 MAX yet, and the 787 still faces some reviews.</p>\n<p>On the positive side of the equation, new orders for the 737 MAX are starting to come in. He expects&nbsp;United Airlines(UAL) to announce an order for about 100 MAX jets in coming days.</p>\n<p>The “roller coaster ride continues” for Boeing stock, he said, noting that “this week’s events probably don’t have an immediate impact on our numbers.” His target price for Boeing stock remains $242 a share. He rates shares at Hold.</p>\n<p>Stallard is a little more bearish than his peers. Overall, about 57% of analysts covering the stock rate the shares at Buy. The&nbsp;average&nbsp;Buy-rating ratio for stocks in the S&amp;P 500 is about 55%. The averageprice targetamong analysts is about $267.</p>\n<p>The biggest issue facing the entire commercial aerospace industry is postpandemic demand. June 2021 U.S. commercial air travel is down&nbsp;roughly 25%&nbsp;compared with 2019 levels. But it is up almost 300% compared with June 2020.</p>\n<p>Things are slowly getting better for the industry. United Airlines, for instance, said Monday it expects&nbsp;a profit in July. It would be the airline’s first monthly profit since January 2020.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boeing’s Newest Jet Is Delayed. Other Issues Are More Important.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoeing’s Newest Jet Is Delayed. Other Issues Are More Important.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/faa-delay-boeing-777x-jet-stock-51624889202?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The commercial aerospace giant Boeing got a bit of bad news about its latest 777 jet, the 777X. The Federal Aviation Administration told the company recently the jet likely won’t be approved for ...</p>\n\n<a href=\"https://www.barrons.com/articles/faa-delay-boeing-777x-jet-stock-51624889202?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BA":"波音"},"source_url":"https://www.barrons.com/articles/faa-delay-boeing-777x-jet-stock-51624889202?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184667820","content_text":"The commercial aerospace giant Boeing got a bit of bad news about its latest 777 jet, the 777X. The Federal Aviation Administration told the company recently the jet likely won’t be approved for commercial service until mid-2023.\nThat timeline, contained in a May letter from the regulator to the company, is longer than investors might have expected, but it isn’t actually all that bad for the stock. Boeing didn’t immediately reply to a request for comment.\nThe 777X took its maiden test flight back in January 2020. That might have put it on track to be approved by mid-2021, based on the way the industry worked a few years ago. Consider that the 737 MAX jet took its initial flight in early 2016 and was approved for service about 14 months later. Deliveries began around mid-2017.\nBut the MAX, of course, was grounded in March 2019 following two deadly crashes within five months. It took 20-plus months of design modifications, additional testing, and regulatory oversight, for Boeing to win permission for the jet to carry passengers again.\nThe MAX situation caused changes at Boeing, including new safety committees, as well as alterations to the FAA’s oversight process. Those shifts could be stretching out the approval process for new planes. The pandemic probably didn’t help the 777x approval timeline either.\nRegardless of the reasons, the approval process has been slow. Boeing investors aren’t thrilled with news of the delay, although deliveries of MAX jets and the recovery of the commercial aerospace business are bigger concerns. Shares were down about 2.8% at $241.56 in early trading, while the S&P 500 and Dow Jones Industrial Average were nearly flat.\nVertical Research Partners analyst Rob Stallard summed up all of the positives and negatives for Boeing in a Monday report. The 777X delay is a regulatory problem, but it is only one of three he mentioned. China, for instance, hasn’t reapproved the 737 MAX yet, and the 787 still faces some reviews.\nOn the positive side of the equation, new orders for the 737 MAX are starting to come in. He expects United Airlines(UAL) to announce an order for about 100 MAX jets in coming days.\nThe “roller coaster ride continues” for Boeing stock, he said, noting that “this week’s events probably don’t have an immediate impact on our numbers.” His target price for Boeing stock remains $242 a share. He rates shares at Hold.\nStallard is a little more bearish than his peers. Overall, about 57% of analysts covering the stock rate the shares at Buy. The average Buy-rating ratio for stocks in the S&P 500 is about 55%. The averageprice targetamong analysts is about $267.\nThe biggest issue facing the entire commercial aerospace industry is postpandemic demand. June 2021 U.S. commercial air travel is down roughly 25% compared with 2019 levels. But it is up almost 300% compared with June 2020.\nThings are slowly getting better for the industry. United Airlines, for instance, said Monday it expects a profit in July. It would be the airline’s first monthly profit since January 2020.","news_type":1,"symbols_score_info":{"BA":0.9}},"isVote":1,"tweetType":1,"viewCount":1734,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124306062,"gmtCreate":1624726385356,"gmtModify":1631889786789,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Yes&nbsp;","listText":"Yes&nbsp;","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/124306062","repostId":"1164137597","repostType":4,"isVote":1,"tweetType":1,"viewCount":1369,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126375104,"gmtCreate":1624546234208,"gmtModify":1631889786790,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126375104","repostId":"1120000038","repostType":4,"isVote":1,"tweetType":1,"viewCount":1191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121223339,"gmtCreate":1624466310121,"gmtModify":1631889786795,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Soon.&nbsp;","listText":"Soon.&nbsp;","text":"Soon.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121223339","repostId":"1145825451","repostType":4,"isVote":1,"tweetType":1,"viewCount":1863,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}